Hana El Sahly

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial
    Hana M El Sahly
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA
    J Infect Dis 205:703-12. 2012
  2. ncbi Pandemic H5N1 influenza vaccine development: an update
    Hana M El Sahly
    Department of Molecular Virology and Microbiology, One Baylor Plaza, BCM MS280, Houston, TX 77030, USA
    Expert Rev Vaccines 7:241-7. 2008
  3. ncbi Clinical data on Fluarix: an inactivated split seasonal influenza vaccine
    Hana M El Sahly
    Department of Molecular Virology and Microbiology, One Baylor Plaza, BCM MS280, Houston, TX 77030, USA
    Expert Rev Vaccines 7:713-9. 2008
  4. ncbi Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans
    H M El Sahly
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States
    Vaccine 27:4905-11. 2009
  5. ncbi Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic
    H M El Sahly
    Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Clin Vaccine Immunol 17:1552-9. 2010
  6. ncbi MF59™ as a vaccine adjuvant: a review of safety and immunogenicity
    Hana El Sahly
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
    Expert Rev Vaccines 9:1135-41. 2010
  7. ncbi Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas
    Hana M El Sahly
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, One Baylor Plaza, BCM MS280, Houston, TX 77030, USA
    J Clin Microbiol 49:2942-5. 2011
  8. ncbi Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations
    Robert L Atmar
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Clin Infect Dis 43:1135-42. 2006

Detail Information

Publications8

  1. ncbi Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial
    Hana M El Sahly
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA
    J Infect Dis 205:703-12. 2012
    ..The immunogenicity of a high hemagglutinin (HA) dose or a second dose of influenza vaccine in human immunodeficiency virus (HIV)-infected individuals has not been fully explored...
  2. ncbi Pandemic H5N1 influenza vaccine development: an update
    Hana M El Sahly
    Department of Molecular Virology and Microbiology, One Baylor Plaza, BCM MS280, Houston, TX 77030, USA
    Expert Rev Vaccines 7:241-7. 2008
    ..There is a suggestion that prepandemic priming against drifted H5N1 variants is possible; however, additional data are needed. Newer approaches using live-attenuated, DNA vaccines and conserved epitopes are currently under development...
  3. ncbi Clinical data on Fluarix: an inactivated split seasonal influenza vaccine
    Hana M El Sahly
    Department of Molecular Virology and Microbiology, One Baylor Plaza, BCM MS280, Houston, TX 77030, USA
    Expert Rev Vaccines 7:713-9. 2008
    ..However, vaccines with improved immunogenicity in at-risk populations, such as the elderly, and with less reliance on growth in eggs, as well as the inherent demanding timelines, are needed to enhance the control of influenza...
  4. ncbi Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans
    H M El Sahly
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, United States
    Vaccine 27:4905-11. 2009
    ....
  5. ncbi Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic
    H M El Sahly
    Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Clin Vaccine Immunol 17:1552-9. 2010
    ..falciparum at low levels compared to sera from placebo recipients or preimmune sera. In conclusion, the EBA-175 vaccine with adjuvant was safe and immunogenic in malaria-naïve subjects...
  6. ncbi MF59™ as a vaccine adjuvant: a review of safety and immunogenicity
    Hana El Sahly
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
    Expert Rev Vaccines 9:1135-41. 2010
    ..Currently, MF59 is under evaluation as an adjuvant with other antigens such as pandemic influenza antigens and cytomegalovirus antigens...
  7. ncbi Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas
    Hana M El Sahly
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, One Baylor Plaza, BCM MS280, Houston, TX 77030, USA
    J Clin Microbiol 49:2942-5. 2011
    ..Previous exposure to quinolones is common among patients with moxifloxacin resistance and warrants more careful evaluation...
  8. ncbi Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations
    Robert L Atmar
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Clin Infect Dis 43:1135-42. 2006
    ..Influenza A/H9N2 viruses can infect humans and are considered to be a pandemic threat. Effective vaccines are needed for these and other avian influenza viruses...